
HIDRADENITIS SUPPURATIVA

NCT07213973

Phase 2, Open-Label Study of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa

Incyte Dermatology

Incyte | SOLVE ON.



1 PRIMARY ENDPOINTS:

- Proportion of patients with TEAEs up to 54 weeks
- Pharmacokinetic parameters in plasma up to 24 weeks

2 SELECT SECONDARY ENDPOINTS:

- Proportion of patients who achieve HiSCR50[a] up to 54 weeks
- Proportion of patients who achieve HiSCR75[b] up to 54 weeks
- Proportion of patients with Skin Pain NRS30[c,d] up to 54 weeks
- Proportion of patients with a ≥3-point decrease in Skin Pain NRS score up to 54 weeks[c]
- Change from baseline in CDLQI score at each visit

For more information, please visit: https://clinicaltrials.gov/study/NCT07213973

[a]Defined as a ≥50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. [b]Defined as a ≥75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.[c]Among patients with baseline Skin Pain NRS score ≥3. [d]Defined as a ≥30% reduction and at least 1-unit reduction from baseline in Skin Pain NRS score.

SELECT INCLUSION CRITERIA

- Adolescents (aged ≥12 to <18 years) with moderate to severe HS for ≥3 months before screening
- Body weight ≥30 kg at both the screening and baseline visits
- HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits
- Total abscess and inflammatory nodule count ≥5 at both the screening and baseline visits
- History of inadequate response, intolerance, or contraindication to at least a 3-month course of ≥1 conventional systemic therapy for HS (oral antibiotic or biologic drug)

SELECT EXCLUSION CRITERIA

- Draining tunnel count of >20 at screening or baseline visit
- Medical history including thrombocytopenia, coagulopathy, or platelet dysfunction; Q-wave interval abnormalities; current or history of certain infections, cancer, lymphoproliferative disorders, and other medical conditions
- Women who are pregnant (or who are considering pregnancy) or breastfeeding

The efficacy and safety of the investigational compound and/or uses discussed have not been established. There is no guarantee that this compound will become commercially available for the use(s) under investigation.

For more information, visit **IncyteClinicalTrials.com** or contact us at **1-855-4MEDINFO** (855-463-3463) or by email at **clintrials@incyte.com**

CDLQI, Children's Dermatology Life Quality Index; EOS, end of study; EOT, end of treatment; HiSCR50, Hidradenitis Suppurativa Clinical Response 50%; HiSCR75, Hidradenitis Suppurativa Clinical Response 75%; HS, hidradenitis suppurativa; NRS, Numerical Rating Scale; TEAE, treatment-emergent adverse event.

ClinicalTrials.gov. Accessed Dec 2025. https://clinicaltrials.gov/study/NCT07213973.

This information is current as of December 4, 2025.

©2025, Incyte. CON-POV-US-0008 12/25